Why Madrigal Pharmaceuticals, Inc. (MDGL) stock moved
Madrigal Pharmaceuticals, Inc. (MDGL) shares fell 3.3% to $535.06 as of July 20, 2026, a moderate decline from the prior close of $553.48. BestStocks flagged the session as a major change for MDGL. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for MDGL, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
MDGL fell 3.3% to $535.06
MDGL fell 3.3% in its latest session, moving from $553.48 to $535.06.
What it means for Madrigal Pharmaceuticals, Inc. investors
For Madrigal Pharmaceuticals, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: MDGL moved +3.67% from $545.36 to $565.40 on 2026-07-08; Madrigal Pharmaceuticals, Inc. (MDGL) moved +2.67% from $514.39 to $528.10 on 2026-07-02. Weighing against that: Negative session, down 3.3%; Madrigal Pharmaceuticals, Inc. (MDGL) moved -4.16% from $560.01 to $536.70 on 2026-07-10. Wall Street's consensus price target sits at $688.40, implying +28.7% upside from $535.06. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 10 days out, the next report is the most likely near-term test of the move.
MDGL price reaction
MDGL last traded at $535.06, down $18.42 (-3.33%) from the previous close of $553.48. The session traded on 0.2× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $509.76 and $565.40, and it currently sits about 45% of the way up that band.
Bullish and bearish analyst opinions on Madrigal Pharmaceuticals, Inc. (MDGL)
The consensus analyst price target on Madrigal Pharmaceuticals, Inc. (MDGL) is $688.40, 28.7% above the recent $535.06. Over the past 90 days analysts logged 0 upgrades, 5 maintains, and 0 downgrades. Here is how the bullish and bearish cases on MDGL line up.
The bullish case
- Wall Street's consensus price target of $688.40 implies +28.7% upside from $535.06.
- The Street's most bullish target is $964.00 (+80.2%).
- MDGL moved +3.67% from $545.36 to $565.40 on 2026-07-08.
- Madrigal Pharmaceuticals, Inc. (MDGL) moved +2.67% from $514.39 to $528.10 on 2026-07-02.
The bearish case
- Negative session, down 3.3%.
- Madrigal Pharmaceuticals, Inc. (MDGL) moved -4.16% from $560.01 to $536.70 on 2026-07-10.
- MDGL fell 2.54% in early trading despite announcing that its collaboration with Ribo reached a first major milestone in advancing novel siRNA therapies for MASH (metabolic dysfunction-associated steatohepatitis).
- Wolfe Research downgraded Madrigal Pharmaceuticals on valuation concerns, coinciding with a 4.1% intraday decline to $514.93.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 20, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for MDGL
Frequently asked questions about MDGL
Why did Madrigal Pharmaceuticals, Inc. (MDGL) stock move?
MDGL fell 3.3% to $535.06. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did MDGL stock fall?
MDGL lost 3.33% ($18.42) versus the prior close of $553.48, last trading at $535.06 on 0.2× average volume.
When is Madrigal Pharmaceuticals, Inc.'s next earnings date?
MDGL's next earnings report is estimated for 2026-07-30 — about 10 days away.
What is the analyst price target for MDGL?
The consensus analyst price target for MDGL is $688.40, about 28.7% above the current $535.06. Over the past 90 days, analysts recorded 0 upgrades, 5 maintains, and 0 downgrades.
How BestStocks tracks MDGL
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared MDGL-specific materiality thresholds, triggering an evidence check. It draws on 7 tracked change events for MDGL, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 20, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.